Biotech
Regenxbio
Regenxbio raises $150M Convertible Note at $2B valuation
$150M
Total Raised
Convertible Note
Latest Round
2008
Founded
350+
Employees
9600 Blackwell Road, Rockville, MD 20850
1 min read
Quick Facts
Valuation
$2B
Latest Round Size
$150M
Latest Round Date
September 2024
Regenxbio: Convertible Note Funding Round
Regenxbio has successfully raised $150M in Convertible Note funding, reaching a valuation of $2B.
Company Overview
Gene therapy delivery platform
Funding Details
The Convertible Note round was led by Third Rock Ventures, with participation from SV Life Sciences, Biomatics Capital Partners.
Company Information
- Headquarters: 9600 Blackwell Road, Rockville, MD 20850
- Founded: 2008
- Employees: 350+
- Category: Biotech
Investment
Regenxbio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Convertible Note
- SV Life Sciences: Verified investor in Convertible Note
- Biomatics Capital Partners: Verified investor in Convertible Note
Key Investors
Third Rock Ventures
Lead Investor
Verified investor in Convertible Note
SV Life Sciences
Investor
Verified investor in Convertible Note
Biomatics Capital Partners
Investor
Verified investor in Convertible Note
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M